Myocardial changes in incident haemodialysis patients over 6-months: an observational cardiac magnetic resonance imaging study by Rutherford, Elaine et al.
1Scientific REpoRTs | 7: 13976  | DOI:10.1038/s41598-017-14481-y
www.nature.com/scientificreports
Myocardial changes in incident 
haemodialysis patients over 
6-months: an observational cardiac 
magnetic resonance imaging study
Elaine Rutherford  1,2, Kenneth Mangion1, Christie McComb1, Elizabeth Bell2, Samantha 
Cockburn1, Mohammed Talle1, Giles Roditi1,3, Paul Welsh1, Rosemary Woodward1, Aleksandra 
Radjenovic1, Allan D. Struthers4, Alan G. Jardine1,2, Colin Berry1, Rajan K. Patel1,2 &  
Patrick B. Mark1,2
Patients commencing on haemodialysis (HD) have an increased risk of cardiovascular events in the 
first year after starting HD compared to those patients established on HD longer. Left ventricular 
(LV) hypertrophy and abnormal myocardial strain predict mortality. There may be changes in the 
myocardium of incident HD patients over a 6-month period of HD which may explain changes in 
cardiovascular risk. We used CMR to consider changes in LV mass, myocardial strain and T1 mapping.  
We examined changes in pre-dialysis highly sensitive troponin T. 33 patients undergoing HD for  
<12 months were recruited. Participants underwent CMR at baseline and after 6-months of standard 
care. 6-months of HD was associated with reduction in LV mass index (Baseline: 78.8 g/m2 follow up: 
69.9 g/m2, p = <0.001). LV global longitudinal strain also improved (Baseline: −17.9%, follow up: 
−21.6%, p = <0.001). Change in T1 time was not significant (Baseline septal T1 1277.4 ms, follow 
up 1271.5 p = 0.504). Highly sensitive troponin T was lower at follow up (Baseline 38.8 pg/L, follow 
up 30.8 pg/L p = 0.02). In incident HD patients, 6-months of HD was associated with improvements 
in LV mass, strain and troponin. These findings may reflect improvement in known cardiac tissue 
abnormalities found in patients over the first year of HD.
Cardiovascular disease is a major cause of morbidity and mortality amongst hemodialysis (HD) patients. 
Echocardiography studies demonstrate that up to three quarters of patients commencing HD have left ventricular 
hypertrophy (LVH)1. Presence of LVH on HD commencement is associated with increased risk of cardiovascular 
and all-cause mortality2,3. The pathophysiology of myocardial disease in HD is complex and in addition to myo-
cardial hypertrophy, involves pump dysfunction, ventricular dilation and myocardial fibrosis4,5. This pathophys-
iology of cardiovascular disease in HD patients is incompletely understood, especially why incident HD patients 
have greater risk of sudden death over the first year of HD than those established on HD for longer6.
Cardiac Magnetic Resonance imaging (CMR) is a leading tool for examining the hearts of HD patients. CMR 
is highly reproducible in these patients where changing volume status make echocardiography less reliable7. CMR 
is better able to characterize cardiac tissue. Although it is not possible to use gadolinium contrast in these patients 
because of concerns regarding nephrogenic systemic fibrosis8, newer non-contrast techniques to characterize 
cardiac tissue are emerging. Recently, native T1 mapping identified abnormalities in uremic hearts compared to 
healthy volunteers, and co-morbid matched patients9,10. These abnormalities are in keeping with those demon-
strated using gadolinium contrast and have been verified in CKD patients with adequate renal function to permit 
gadolinium use11,12.
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Myocardial strain, often measured as global longitudinal strain (GLS), a measure of myocardial deformation 
throughout the cardiac cycle, is more directly associated with cardiomyocyte metabolism than LV ejection frac-
tion (LVEF)13. Reduction in magnitude of peak strain is associated with reduced myocardial contraction and 
could be associated with fibrosis14. CMR GLS has been demonstrated to be impaired in several renal populations, 
including in CKD, incident and prevalent HD patients, as well as correlating with cardiac histology in animal 
models of kidney failure9,10,12,15.
We undertook an observational study to interrogate the hearts of incident HD patients over a 6-month 
period. We sought to identify detectable changes in cardiac structure, function and composition using CMR. 
We assessed associations between these and clinical data. We hypothesized that haemodialysis would affect 
myocardial contractility (measured by myocardial strain) and could reduce or reverse diffuse fibrosis, measured 
by native T1 mapping. We hypothesized changes in biomarkers associated with myocardial stress would occur 
(highly-sensitive troponin T (hs-TropT) and N-Terminal Pro-B type Natriuretic Peptide (NT-ProBNP)).
Results
Participants. Thirty-four patients consented to participate; 32 participants completed baseline imaging, one 
participant died after consenting but prior to study visit, another withdrew consent before imaging. Twenty-
four participants (75% of consented participants) completed baseline and follow-up visits. Six participants were 
transplanted during the study and 2 participants withdrew consent. No participants died during follow up. Mean 
participant age was 61.2 ± 13.4 years, 62.5% were male. Median duration of HD at baseline was 5 months (inter-
quartile range (IQR) 3.8–8 months). Baseline demographic data for study participants completing the study are 
shown in Table 1.
Left Ventricular Mass and Function. LV mass indexed to body surface area (LVMI) reduced following 6 
months of HD. Baseline LVMI was 78.8 ± 18.6 g/m2 versus follow up LVMI 69.9 ± 19.3 g/m2, p = <0.001 (Fig. 1). 
There was no change in LVEF between baseline and follow up visits (baseline LVEF 64.3 ± 10.0%, follow up LVEF 
61.7 ± 9.9 p = 0.13). End diastolic volumes (EDV) and end systolic volumes (ESV) were unchanged from baseline 
to follow up. Table 2 summarises clinical, CMR and biomarker indices at baseline and follow up (Table 2).
Native T1 Times. Native T1 times were unchanged following 6 months of HD. Baseline global T1 time: 
1263.4 ± 24.8 ms, follow up global T1 time; 1259.3 ± 32.2 ms, p = 0.59. Mean septal T1 time baseline; 
1277.4 ± 28.2 ms, follow up 1271.5 ± 35.4 ms, p = 0.50.
Myocardial Strain. Reflecting improved myocardial compliance, magnitude of GLS and strain rate both 
increased following 6 months of HD. Baseline GLS: −17.9 ± 5.3%, follow up GLS-21.6 ± 6.1%, p = <0.001 
(Fig. 2). Baseline strain rate: 0.97 ± 0.28 s−1, follow up strain rate 1.184 ± 0.46 s−1, p = 0.01. There was no sig-
nificant change in early diastolic strain rate from baseline to follow up. Baseline early diastolic strain rate 
1.04 ± 0.33 s−1, follow up early diastolic strain rate 1.16 ± 0.43 s−1, p = 0.14.
Biomarkers. There was no change in NT-proBNP from baseline to follow up (median baseline NT-proBNP 
3348 (IQR 1718–5112) pg./ml, follow up 2317 (IQR 1559–7028 pg/ml p = 0.44). There was a reduction in 
Patient Characteristics Patients [N = 24]
Age (years) 61.2 ± 13.4
Male (%) 62.5 [15]
BMI (kg/m2) 24 (21.7–29.5)
Duration RRT (months) 5 (3.8–8)
Primary Renal Diagnosis
Diabetic Nephropathy (%) 29.2 [7]
Renovascular Disease (%) 16.7 [4]
Glomerulonephritis (%) 12.5 [3]
Polycystic Kidney Disease (%) 4.2 [1]
Other (%) 20.7 [5]
Unknown (%) 16.7 [4]
Past Medical History
Diabetes (%) 29.2 [7]
Hypertension (%) 54.2 [13]
Stroke (%) 16.7 [4]
Myocardial Infarction (%) 12.5 [3]
Ischaemic Heart Disease (%) 20.7 [5]
Drug history
B-Blocker 3 [13]
ACE-Inhibitor 19 [79]
Table 1. Baseline Participant Demographic Data. Data is shown as mean ± standard deviation, % [number of 
participants] or median (interquartile range).
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hs-tropT from baseline to follow up (Baseline median hs-TropT: 38.8 (IQR 24.5–49.5) pg/L, follow up: 30.8 (IQR 
18.9–57.6) pg/L, p = 0.02).
Clinical Data. There was no change in URR, blood pressure (BP) or ultrafiltration volumes from baseline to 6 
months follow up. Weight at end of dialysis the session before imaging was unchanged from baseline to follow up. 
There were no significant changes in any routinely collected blood test results during the study.
Relationships between T1 times and left ventricular indices. There were correlations between base-
line LVMI and baseline septal T1 time (Pearson’s R = 0.566, p = 0.04). At follow up, this correlation was not sta-
tistically significant (Pearson’s R = 0.396, p = 0.055). Similarly, global T1 time at baseline correlated with baseline 
LVMI (Pearson’s R = 0.585 p = 0.003), however follow up global T1 time was not correlated with follow up LVMI 
Figure 1. Box plot of Left Ventricular Mass Index at baseline and follow up.
Variable Baseline [N = 24] Follow Up [N = 24] P value
Systolic BP (mmHg) 140 ± 19 140 ± 21 0.99
Diastolic BP (mmHg) 78 (66–83) 73 (63–81) 0.29
Haemoglobin (mg/dL) 109 (99–118) 109 (104–115) 0.65
Urea Reduction Ratio (%) 71.8 ± 8.4 72.3 ± 7.3 0.70
30-day mean ultrafiltration volume (ml) 1718 ± 905 1703 ± 937 0.93
Post HD weight (kg) 65.6 (60.5–82.4) 66.2 (59.7–80.4) 0.15
Albumin (g/L) 33.5 (32–35) 35 (33.8–36.3) 0.08
Phosphate (mmol/L) 1.73 ± 5.4 1.69 ± 5.3 0.59
Corrected Calcium (mmol/L) 2.30 ± 0.12 2.29 ± 0.13 0.96
Highly sensitive Troponin T (pg/L)* 38.8 (24.5–49.5) 30.8 (18.9–57.6) 0.02
NT-ProBNP (pg/ml)* 3348 (1718–5112) 2317 (1559–7028) 0.43
Ejection Fraction (%) 64.3 ± 10.0 61.7 ± 9.9 0.13
End Diastolic Volume (ml) 143.2 (136.7–157.6) 146.9 (127–168) 0.78
End Systolic Volume (ml) 50.9 (40.7–58.4) 53.1 (42.2–64.6) 0.16
Stroke Volume (ml) 95.9 ± 21.9 90.6 ± 17.5 0.15
Left Ventricular Mass (g) 139.1 (112.4–163.7) 114.0 (100.9–155) <0.001
LVMI (g/m2) 78.8 ± 18.6 69.9 ± 19.3 <0.001
Global Longitudinal Strain (%) −17.9 ± 5.3 −21.6 ± 6.1 <0.001
Strain Rate (s−1) 0.97 ± 0.28 1.184 ± 0.46 0.01
Early Diastolic Strain Rate (s−1) 1.04 ± 0.33 1.16 ± 0.43 0.15
Global T1 Time (ms) 1263.4 ± 24.8 1259.3 ± 32.2 0.59
Septal T1 Time (ms) 1277.4 ± 28.2 1271.5 ± 35.4 0.50
Table 2. Clinical, biochemical and CMR parameters at baseline and follow up. Data is shown as mean ± standard 
deviation, or median (interquartile range). Abbreviations: LVMI; left ventricular mass indexed to body surface 
area, NT-ProBNP; N-terminal pro beta natriuretic peptide. *NT-ProBNP and hs-tropT were available for 22 
participants only.
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(Pearson’s R = 0.350, p = 0.09). The difference in LVMI over the study period also correlated with difference in 
septal T1 time (R = 0.454, p = 0.03), but not difference in global T1 time (R = 0.375, p = 0.07). There was no asso-
ciation demonstrated between EDV, ESV or LVEF and T1 times.
Relationships between myocardial strain and left ventricular indices. At baseline, GLS was 
related to LVEF (Pearson’s R = −0.601, p = 0.002), LVMI (Pearson’s R = 0.621, p = 0.001), EDV (Spearman’s 
R = 0.470, p = 0.02) and ESV (Spearman’s R = −0.577, p = 0.03. At follow up similar associations with GLS were 
demonstrated for LVEF and LVMI but not EDV or ESV: GLS and LVEF (Pearson’s R = −0.425, p = 0.04), LVMI 
(Pearson’s R = 0.496, p = 0.01), EDV (Spearman’s R = 0.264, p = 0.21). There was no correlation between differ-
ence in LVMI and the difference in GLS.
Relationship between Myocardial Strain and native T1. At baseline, GLS correlated with global native 
T1 relaxation time (Pearson’s R = 0.461, p = 0.02) and with septal T1 (Pearson’s R = 0.434, p = 0.03). At follow up 
this relationship was not seen: follow up GLS and global native T1 (Pearson’s R = 0.101, p = 0.64), follow up GLS 
and septal T1 (Pearson’s R = 0.062, p = 0.77). There was no correlation between change in GLS and change in 
native T1 times. There were no relationships between strain rate or early diastolic strain rate and native T1 time.
Relationship between Biomarkers and CMR Findings. At both baseline and follow up, there were no 
correlations demonstrated between any measure of NT-proBNP, hs-tropT or any LV indices, native T1 or myo-
cardial strain.
Patients where Septal T1 times reduced compared to where it did not. Overall there was a pattern 
of improvement in cardiac parameters in some participants but not others. Figure 3 illustrates changes seen in a 
typical patient whose parameters improved.
Septal T1 times improved in 66.7% of patients. Patients whose septal T1 time improved had higher base-
line septal T1 compared with those whose T1 time did not improve (1288.1 ± 28.1 ms, versus 1256.0 ± 11.6 ms, 
p = 0.006). By follow up, septal T1 time was lower in the ‘improving’ group compared to the ‘non-improving’ 
group (follow up septal T1 time improvers 1258.8 ± 22.2 ms, non-improvers 1296.9 ± 37.3 ms, p = 0.01).
Patients with reduction in septal T1 over the study duration had evidence of reduced myocardial contrac-
tility at baseline, as their baseline GLS was reduced in magnitude compared to those whose T1 time did not fall 
Figure 2. Scatter plots of Left Ventricular Mass Index and Global longitudinal strain at baseline and follow-up.
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(Improvers GLS −16.27 ± 4.38, non-improvers, GLS −21.05 ± 5.94, p = 0.04). By follow up, there was no signifi-
cant difference in GLS between the groups.
Although overall LVMI was no different at baseline or follow up in septal T1 time improvers versus 
non-improvers, the difference in LVMI over during the study was greater in those whose T1 time fell (difference 
in LVMI improvers: −12.8 ± 10.4 g/m2, non-improvers: −3.3 ± 5.7 g/m2, p = 0.009).
There were no significant differences in hs-tropT, NT-proBNP, BP, BMI, age, duration of RRT, URR, mean UF 
volumes, corrected calcium or haemoglobin between those whose septal T1 time fell and those whose septal T1 
time did not. Phosphate was higher at baseline and follow up in those whose septal T1 time fell (T1 improvers: 
baseline phosphate 1.92 ± 0.52, non-improvers 1.35 ± 0.33, p = 0.01). There was no difference in incidence of 
diagnosis of congestive cardiac failure, hypertension, ischemic heart disease, previous myocardial infarction or 
diagnosis of diabetes between those whose septal T1 fell and those whose septal T1 did not.
Discussion
This is the first study to investigate effects of 6-months of HD on incident HD patients utilizing multi-parametric 
CMR with native T1 mapping and feature tracking myocardial strain analysis. We observed trends suggest-
ing that there is an association between HD and an improvement in myocardial biomechanics (identified by 
feature-tracking derived GLS), and regression of LVH. These results require validation in a larger cohort of 
patients.
The improvements in GLS and strain rate are encouraging. Previous studies have shown that GLS measured 
using speckle tracking echocardiography correlates with other markers of uremic cardiomyopathy, including 
fibrosis on histology15. That regression in LVMI and improvement in GLS and strain rate occurred together is sug-
gests that the higher the LVMI, the less efficient left ventricular contraction and relaxation are and that as LVMI 
regresses, the ventricle becomes more compliant. As suggested by correlation of reduction in septal T1 relaxation 
times with reduction in LVMI, our study findings may indicate that as LVMI regresses, fibrosis also regresses, 
Figure 3. Typical changes in a study participant whose cardiac parameters improved over the duration of the 
study. Panels A–C are baseline images, panels D–F are follow up images. Panel A shows a short axis view of 
the left ventricle on baseline imaging, the myocardial thickness measures 1.7 cm, by follow up (panel D) the 
diameter had reduced to 1.4 cm. Panel B shows a typical T1 map obtained during the study, an interventricular 
septal segment has been drawn on and shows a T1 time of 1294 ms, by follow up (panel E) the corresponding 
segment had a noticeable reduction in T1 time to 1211 ms. Panel C shows a representative graph of global 
longitudinal strain; the horizontal axis is time throughout the cardiac cycle and the vertical axis shows amount 
of myocardial displacement. On comparison of panel C with panel F the displacement is greater in panel F, 
representing an improvement in myocardial strain mechanics over the study follow up period.
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resulting in improved myocardial biomechanics leading to enhancement in GLS and strain rate. However, with-
out histological confirmation, this is speculative.
Regression of LVMI in incident HD patients has been demonstrated previously. Regression in LVMI over time 
in patients new to HD was shown in an observational echocardiography study, where LVMI regressed in 48% 
of patients following one year of HD16. Another study considered echocardiographic changes in patients with 
end stage renal disease and heart failure17. Echocardiography was performed up to 3 months prior to HD initi-
ation and again 8.6 ± 5.2 months after starting HD. There was a significant reduction in LVMI (mean reduction 
24.3 ± 35.4 g/m2). The authors concluded this was due to improvement in volume status17. Although improved 
volume status is possibly a factor in the reduction in LVMI seen in our study, we saw no changes in EDV or ESV. 
Additionally, mean ultrafiltration volumes for 30 days prior to imaging did not change from baseline to follow up. 
Supporting the notion that change in LVMI in our study was not purely related to volume changes, there was no 
change in patient weight from baseline to follow up. However, we cannot exclude that overall improvement in vol-
ume status contributed to regression in LVMI and improvements in myocardial strain. Conversely, a continued 
rise in LVMI after dialysis initiation has been demonstrated using echocardiography, however it may be that tim-
ing of imaging, changing volume status or other co-morbidities in previous work contributed to this difference18.
Additionally, our data do not support the theory that LVMI regression and improvement in GLS were due to 
better BP control, as there was no difference in BP from baseline to follow up. Similarly, other makers of dialysis 
efficacy such as URR, calcium and phosphate were unchanged. That the changes in imaging abnormalities are 
independent of BP is not entirely surprising. A CMR study comparing patients with CKD and hypertensive 
patients, showed that LVMI was highest in the CKD group and that GLS was worse in the CKD group despite the 
hypertensive group having the highest BP12.
We did not observe reductions in either global or septal T1 relaxation times over the study duration, although 
there was an absolute difference in magnitude of T1 time of 5 ms. A larger sample size, or longer follow up dura-
tion may have led to a statistically significant change in T1 time as there were some indications in the study 
that T1 is interrelated to other markers of tissue abnormality. In fact, baseline septal T1 correlated with both 
GLS and LVMI. Change in septal T1 time also correlated with the difference in LVMI over a 6-month period. 
However, despite supporting evidence from histological studies19–21, without tissue correlation, we cannot be 
certain that changes in LVMI, myocardial strain and T1 times are reflective of an improvement in myocardial 
tissue abnormalities.
Although this was a relatively small single centre study, improvements seen in CMR derived cardiac parame-
ters are of potentially important clinical significance. Participants whose T1 times improved had higher baseline 
T1 relaxation times and poorer baseline GLS. The possibility of regression to the mean should be considered. To 
attempt to address this, we investigated the effect of paired measures and the effect of regression to the mean by 
ANCOVA analysis- p 0.001 for LVMI, and p < 0.001 for GLS. Reassuringly, even after weighting for within sub-
ject change, the difference in measurements was still significant. It is too early to tell whether the patients whose 
cardiac parameters improved will subsequently have reduced cardiac morbidity and mortality. However, there is a 
reasonable body of evidence that LVH in HD is associated with an increased cardiac morbidity, cardiac mortality 
and all-cause mortality2,3. Echocardiography derived GLS also predicts mortality in patients with CKD22,23.
Limitations of our study include it being single centre, and small sample size. Patients were recruited on 
average with a 5 month HD duration. Our power calculation was based on data using gadolinium, to repro-
duce our work it would be possible to base sample sizes on T1 data in dialysis patients9,10. However, we used a 
multi-parametric CMR protocol and biochemical markers so our study population was well characterized. Future 
studies would include a multicentre approach with larger sample size, and potentially with histological validation 
of T1.
In summary, this study demonstrated that in incident HD patients, 6 months of HD was associated with 
improved LVMI and myocardial strain. Although no significant difference in T1 times from baseline to follow 
up was seen, change in septal T1 time associated with change in LVMI. We consider that these findings reflect 
improvement in tissue abnormalities known to be associated with renal failure. However, without tissue correla-
tion we cannot be certain - future studies with findings correlated with cardiac histology are of interest.
Materials and Methods
Study Participants. Thirty-four HD participants consented to participate in the Cardiac Uraemic fibro-
sis Detection in DiaLysis patiEnts study (CUDDLE study ISRCTN99591655). The West of Scotland Research 
Ethics Service (13/WS/0301) approved the study. The study was carried out in accordance with the declaration 
of Helsinki. Participants were eligible if they had been receiving HD for <12 months. Exclusion criteria included 
atrial fibrillation as this impairs cardiac-gating of images, or CMR contraindications24. All patients provided 
written, informed consent and received usual thrice weekly dialysis care for the study duration. Participants who 
underwent renal transplantation during follow up were withdrawn from the study.
CMR Imaging Technique. All participants underwent CMR on a post-dialysis day on a 3 T scanner 
(MAGNETOM Verio, or Prisma, Siemens, Erlangen, Germany) at baseline and after 6-months of HD. Patients 
who underwent dialysis on a Monday/Wednesday/Friday schedule were imaged on a Tuesday or Thursday, 
Tuesday/Thursday/Saturday patients were imaged on Wednesdays or Fridays. A double radio-frequency array coil 
(anterior and posterior) was used. The imaging protocol included cine magnetic resonance with steady-state free 
precession and T1 mapping sequences25. A cine short-axis stack of the LV was performed. Basal, mid and apical 
T1 maps were acquired using motion-corrected, optimized, modified Look-Locker inversion recovery sequences 
without contrast. Typical T1 acquisition parameters were: slice thickness 6.0 mm, voxel size: 1.9 × 1.9 × 6.0 mm, 
field of view 340 mm × 272 mm, flip angle 35 degrees, minimum T1 180 ms, inversion-time increment 80 ms, 
repetition time 267.84 ms, bandwidth 1085 Hertz/pixel.
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Image Analysis. LV indices were analysed by a single blinded observer as previously described9. For T1 
maps, LV contours were drawn onto colour-enhanced spatially co-registered maps. The anterior right ventricular 
insertion point was used as reference and T1 maps were segmented corresponding with the American Heart 
Association (AHA) 16-segment model26. Segmental AHA regions were delineated by user-defined border delin-
eation on Siemens Argus software. T1 times were measured in each segment. Care was taken to ensure adequate 
margins from tissue interfaces such as between the blood pool and myocardium. After removal of any segments 
affected by artefact, global T1 time was calculated as the mean of remaining segments. Septal T1 time was calcu-
lated by averaging remaining AHA anteroseptal, inferoseptal, and septal segments (i.e. segments 2, 3, 8, 9, 14). 
To determine GLS, strain rate and end-diastolic strain rate feature-tracking software (TomTec, Diogenes Image 
Arena, Munich, Germany) was used. On horizontal long-axis cine acquisition, the end-diastolic frame was iden-
tified for each image and endocardial borders were delineated. The delineated contour was then automatically 
propagated throughout the cardiac cycle and GLS, strain rate and early diastolic strain rate calculated27.
Biomarkers. Pre-dialysis blood samples at baseline and after 6-months follow up were frozen (−80 °C) and 
thawed for analysis of hs-tropT and NT-proBNP in a single batch using validated assays (e411, Roche Diagnostics, 
Burgess Hill, UK). All samples were analysed using manufacturers’ protocols and calibrations. Routine blood tests 
including haemoglobin, urea reduction ratios (URR), albumin, corrected calcium and phosphate were avail-
able from electronic patient records (EPR). EPR were used for medical and dialysis history including pre-and 
post-dialysis weights and ultrafiltration volumes 30 days prior to imaging.
Statistics. Statistical analyses were performed using SPSS version 22 (Armonk, NY). Normality was 
tested using visual distribution checks and the Kolmogorov-Smirnov test. Paired t tests (for parametric data) 
and Wilcoxon-Signed Rank tests (for nonparametric data) were used to compare continuous indices between 
time points within HD patients. Independent t tests (for parametric data) and Mann-Whitney U tests (for non-
parametric data) were used to compare between group differences. Correlations between continuous indices 
were assessed using Pearson’s and Spearman’s correlation coefficients for parametric and nonparametric data, 
respectively.
The power calculation was based on mass of fibrotic tissue detected with gadolinium as previously published11 
as at commencement of this study design there were no data to inform distribution of T1 times in HD patients.
Data from patients studied with gadolinium showed that distribution of fibrosis, when present was normally 
distributed with standard deviation 7 g. If the true difference in mean difference in volume of fibrotic tissue 
detected at CMR in matched pairs is 4.5 g, we determined 27 patients were needed (paired t-test at 0 and 6 
months) to detect this difference with power of 90% and type I error probability of 0.05. Allowing for a 20% drop-
out due to transplant, death and co-morbid disease, we aimed to recruit 35 patients.
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